Diligence memo · auto-generated · as of July 2, 2026
LifeMine Therapeutics, Inc.
LifeMine Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
LifeMine Therapeutics, Inc. operates in Biotechnology, based in Cambridge.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
LifeMine Therapeutics, Inc. has raised $30M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $70M on 2017-09-15.
Most recent recorded round closed around 2017-09-15.
Valuation (modeled)modeled
Provath models LifeMine Therapeutics, Inc. at approximately $995M (range $50M–$3.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.25× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era. Within the normal band (125% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 8.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 75% of Biotechnology peers (4293 compared).
Modeled value ranks above 90% of those peers.
Closest niche peers: Liquid BioScience, Inc., Amphivena Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Tetra Discovery Partners, Inc., ECM Therapeutics, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.